427 related articles for article (PubMed ID: 28683725)
1. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
[TBL] [Abstract][Full Text] [Related]
3. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
[TBL] [Abstract][Full Text] [Related]
4. A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples.
Lopez MF; Mikulskis A; Kuzdzal S; Golenko E; Petricoin EF; Liotta LA; Patton WF; Whiteley GR; Rosenblatt K; Gurnani P; Nandi A; Neill S; Cullen S; O'Gorman M; Sarracino D; Lynch C; Johnson A; Mckenzie W; Fishman D
Clin Chem; 2007 Jun; 53(6):1067-74. PubMed ID: 17463175
[TBL] [Abstract][Full Text] [Related]
5. [Identification of serum peptide biomarker for ovarian cancer diagnosis by Clin-TOF-II-MS combined with magnetic beads technology].
Xiu L; Li N; Wang WP; Chen F; Yuan GW; Sun YC; Zhang R; Li XG; Zuo J; Li N; Cui W; Wu LY
Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1188-1195. PubMed ID: 34794222
[No Abstract] [Full Text] [Related]
6. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating Peptide associated with pancreatic cancer.
Fiedler GM; Leichtle AB; Kase J; Baumann S; Ceglarek U; Felix K; Conrad T; Witzigmann H; Weimann A; Schütte C; Hauss J; Büchler M; Thiery J
Clin Cancer Res; 2009 Jun; 15(11):3812-9. PubMed ID: 19470732
[TBL] [Abstract][Full Text] [Related]
7. Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.
Wu S; Xu K; Chen G; Zhang J; Liu Z; Xie X
Int J Clin Oncol; 2012 Apr; 17(2):89-95. PubMed ID: 21638024
[TBL] [Abstract][Full Text] [Related]
8. Detection of lung cancer using plasma protein profiling by matrix-assisted laser desorption/ionization mass spectrometry.
Shevchenko VE; Arnotskaya NE; Zaridze DG
Eur J Mass Spectrom (Chichester); 2010; 16(4):539-49. PubMed ID: 20625202
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers.
Wang H; Kachman MT; Schwartz DR; Cho KR; Lubman DM
Proteomics; 2004 Aug; 4(8):2476-95. PubMed ID: 15274142
[TBL] [Abstract][Full Text] [Related]
10. [Identification of serum biomarkers for ovarian cancer using protein chips and time of flight mass spectrometry technology].
Wang Q; Li L; Li DR; Zhang W; Wei X; Zhang JQ; Tang Y
Zhonghua Fu Chan Ke Za Zhi; 2006 Aug; 41(8):544-8. PubMed ID: 17083841
[TBL] [Abstract][Full Text] [Related]
11. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.
Nanni P; Parisi D; Roda G; Casale M; Belluzzi A; Roda E; Mayer L; Roda A
Rapid Commun Mass Spectrom; 2007; 21(24):4142-8. PubMed ID: 18022963
[TBL] [Abstract][Full Text] [Related]
12. Proteome profiling of human epithelial ovarian cancer cell line TOV-112D.
Gagné JP; Gagné P; Hunter JM; Bonicalzi ME; Lemay JF; Kelly I; Le Page C; Provencher D; Mes-Masson AM; Droit A; Bourgais D; Poirier GG
Mol Cell Biochem; 2005 Jul; 275(1-2):25-55. PubMed ID: 16335783
[TBL] [Abstract][Full Text] [Related]
13. Detection of Epithelial Ovarian Cancer using C8Magnetic Bead Separation and MALDI-TOF Plasma Proteome Profiling in Egyptian Females.
Rizk MM; Sharaki OA; Meleis ME; Younan DN; Elkial AA; Moez P
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3603-3609. PubMed ID: 31870100
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
[TBL] [Abstract][Full Text] [Related]
15. Proteomic Profiling of Invasive Ductal Carcinoma (IDC) using Magnetic Beads-based Serum Fractionation and MALDI-TOF MS.
Yang J; Zhu J; He K; Zhao LY; Liu LY; Song TS; Huang C
J Clin Lab Anal; 2015 Jul; 29(4):321-7. PubMed ID: 25130542
[TBL] [Abstract][Full Text] [Related]
16. Investigation of early and advanced stages in ovarian cancer using human plasma by differential scanning calorimetry and mass spectrometry.
Kim NA; Jin JH; Kim KH; Lim DG; Cheong H; Kim YH; Ju W; Kim SC; Jeong SH
Arch Pharm Res; 2016 May; 39(5):668-76. PubMed ID: 27002828
[TBL] [Abstract][Full Text] [Related]
17. Performance of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) in diagnosis of ovarian cancer: a systematic review and meta-analysis.
Li K; Pei Y; Wu Y; Guo Y; Cui W
J Ovarian Res; 2020 Jan; 13(1):6. PubMed ID: 31924227
[TBL] [Abstract][Full Text] [Related]
18. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
[TBL] [Abstract][Full Text] [Related]
19. Identification of Potential Biomarkers and Metabolic Profiling of Serum in Ovarian Cancer Patients Using UPLC/Q-TOF MS.
Yang W; Mu T; Jiang J; Sun Q; Hou X; Sun Y; Zhong L; Wang C; Sun C
Cell Physiol Biochem; 2018; 51(3):1134-1148. PubMed ID: 30476914
[TBL] [Abstract][Full Text] [Related]
20. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.
Timms JF; Cramer R; Camuzeaux S; Tiss A; Smith C; Burford B; Nouretdinov I; Devetyarov D; Gentry-Maharaj A; Ford J; Luo Z; Gammerman A; Menon U; Jacobs I
Clin Chem; 2010 Feb; 56(2):262-71. PubMed ID: 20093557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]